Article
Oncology
Catherine Sarre-Lazcano, Sinziana Dumitra, Marco Fiore
Summary: Pelvic soft tissue sarcomas (PSTS) are a rare and heterogeneous group of tumors that differ from retroperitoneal sarcomas (RPS). Adequate imaging and preoperative biopsy are crucial for differential diagnosis and treatment planning. Surgical approach and multidisciplinary teamwork are essential due to anatomic constraints and potential complications. Early referral to specialized centers is recommended for optimal resection and improved survival. International consensus on PSTS treatment is needed, similar to recent efforts for RPS.
Article
Oncology
Dietmar Dammerer, Johannes Neugebauer, Matthias Braito, Moritz Wagner, Markus Neubauer, Lukas Moser, Markus Suess, Michael Liebensteiner, David Putzer
Summary: Soft tissue sarcomas are rare malignant tumors originating in the mesenchyme, with over 80 different types identified. This study investigated the local recurrence rate in 35 individuals with soft tissue sarcomas treated at the University Hospital for Orthopaedics Innsbruck from 2010-2016. The treatment regimen consisting of surgical resection, radiotherapy, and chemotherapy achieved high local control rates for extremities and retroperitoneal sarcomas.
Review
Oncology
Changkai Zhou, Xue Chen, Ying Huang, Qi Zhang, Shu Zhu, Wei Fu
Summary: This article discusses the progress made in the use of nanotechnology for the diagnosis and treatment of soft tissue sarcomas (STS) and highlights the future prospects of STS multimodality therapy.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
William G. J. Kerrison, Alexander T. J. Lee, Khin Thway, Robin L. Jones, Paul H. Huang
Summary: Immunotherapy in soft tissue sarcoma has become a popular and promising therapeutic strategy, with immune checkpoint inhibitors showing effectiveness in certain subtypes. Combination therapies have also shown enhanced response rates.
Review
Cell Biology
Stefania Kokkali, Eleni Georgaki, Georgios Mandrakis, Claudia Valverde, Stamatios Theocharis, Filomena De Nigris
Summary: The clinical utility of next-generation sequencing (NGS) in the treatment of soft tissue sarcoma (STS) is still controversial, with limited retrospective studies providing data on the use and efficacy of targeted treatment. Despite detailed reports on different gene mutations, fusions, or amplifications, there is a lack of information on the effectiveness of targeted therapies in STS.
Article
Reproductive Biology
Raul Ayala Davila, Cassy Spiller, Danyon Harkins, Tracey Harvey, Philip W. Jordan, Richard M. Gronostajski, Michael Piper, Josephine Bowles
Summary: Members of the NFI family play essential roles in stem cell biology during development, and their expression patterns in the seminiferous tubules show distinct patterns. NFIX is found to be critical for meiotic progression during spermatogenesis. Its deletion leads to defective synaptonemal complex and unrepaired DNA double-strand breaks in spermatocytes.
BIOLOGY OF REPRODUCTION
(2022)
Review
Cell Biology
Shadi Hames-Fathi, Steven W. G. Nottley, Nischalan Pillay
Summary: This article reviews recent advances in the diagnosis and treatment of undifferentiated soft tissue sarcoma (USTS), including genomic sequencing, cancer evolution and heterogeneity studies, and immunotherapy. The critical role of pathologists in the diagnosis and treatment of USTS patients is emphasized.
Article
Oncology
Markus Albertsmeier, Annelore Altendorf-Hofmann, Lars H. Lindner, Rolf D. Issels, Eric Kampmann, Hans-Roland Duerr, Martin K. Angele, Frederick Klauschen, Jens Werner, Achim A. Jungbluth, Thomas Knoesel
Summary: This study demonstrates that VISTA is broadly expressed across subtypes of soft tissue sarcoma and is associated with increased tumor-infiltrating lymphocytes, PD-1, PD-L1, and CD3 expression. Patients with VISTA(+) tumors exhibit improved survival.
Review
Medicine, General & Internal
Grace C. Blitzer, Poonam Yadav, Zachary S. Morris
Summary: Soft tissue sarcomas are rare tumors that primarily occur in the extremities, trunk, and retroperitoneum. Surgical resection with clear margins is the main treatment option for localized tumors, while radiation therapy can be used to reduce local recurrence. MRI-guided radiotherapy offers advantages in target delineation and differentiation from normal tissues, particularly for unresectable tumors.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Alessandra Buja, Massimo Rugge, Matteo Barillaro, Andrea Miatton, Saveria Tropea, Claudia Cozzolino, Manuel Zorzi, Antonella Vecchiato, Paolo Del Fiore, Antonella Brunello, Vincenzo Baldo, Carlo Riccardo Rossi, Simone Mocellin
Summary: This study aimed to compare the pathological and clinical features of retroperitoneal soft-tissue sarcomas (RPS) and non-RPS, and analyze if the hazard ratio for short-term mortality differs between RPS and non-RPS after adjusting for baseline differences. The analysis found that RPS accounted for 22.8% of cases, with different characteristics compared to non-RPS. The retroperitoneum site was an independent prognostic factor associated with worse overall survival in sarcoma patients.
Review
Oncology
Andrea Sambri, Emilia Caldari, Michele Fiore, Riccardo Zucchini, Claudio Giannini, Maria Giulia Pirini, Paolo Spinnato, Alberta Cappelli, Davide Maria Donati, Massimiliano De Paolis
Summary: There is still lack of standardized description for assessing margin status of soft tissue sarcomas, highlighting the need for uniform classification and standardization.
Review
Oncology
Gyuhee Seong, Sandra P. D'Angelo
Summary: Soft tissue sarcoma is a rare and aggressive disease with high metastasis rate. Traditional approaches such as surgery, radiation, and chemotherapy have limited efficacy, leading to the exploration of novel immunotherapy. Immune checkpoint inhibitors have shown promising results in treating soft tissue sarcoma, and combination therapies with chemotherapy, targeted therapy, and radiation have also been effective. Adoptive cell therapies, especially genetically modified T-cell receptor therapy, have demonstrated durable responses. CAR-T cell therapies hold great potential in targeting specific antigens in soft tissue sarcoma with reliable response.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Esther Martinez-Font, Marina Perez-Capo, Oliver Vogler, Javier Martin-Broto, Regina Alemany, Antonia Obrador-Hevia
Summary: Soft tissue sarcomas are a heterogeneous group of rare tumors originating from mesenchymal tissue, with chemotherapy based on doxorubicin remaining the standard first-line treatment. Understanding the molecular alterations of the WNT signaling pathway in STS is crucial for developing new therapeutic approaches and identifying drug targets.
Article
Oncology
Patrick Groothuis, Nicola Penel, Antoine Italiano, Nuria Kotecki, Fred Dijcks, Wim Dokter
Summary: Soft tissue sarcoma (STS) is a difficult-to-treat malignancy originating from mesenchymal or connective tissues. The molecule 5T4/trophoblast glycoprotein is found to be prominently expressed on the cell surface of many STS subtypes, making it a potential target for targeted therapies. Further investigation is warranted to determine whether this antigen could trigger an anti-tumor immune response or serve as a target for delivering more potent toxins through antibody drug conjugates, as it is expressed in more than 50% of other STS subtypes.
Article
Oncology
Chiara Giraudo, Giulia Fichera, Paolo Del Fiore, Simone Mocellin, Antonella Brunello, Marco Rastrelli, Roberto Stramare
Summary: This study evaluated the prognostic role of radiomic variables extracted from ADC maps in patients with soft tissue sarcomas. The radiomic feature Imc1 was found to be a predictor of metastatic spread and correlated with the tumor grade.
FRONTIERS IN ONCOLOGY
(2022)
Review
Obstetrics & Gynecology
Huiying Jie, Mingpeng Zhao, Odai Ali Mohammad Alqawasmeh, Carol Pui Shan Chan, Tin Lap Lee, Tinchiu Li, David Yiu Leung Chan
Summary: The article discusses the issue of immature oocytes retrieved from IVF and clinical IVM cycles, proposes naming them 'Medical Unusable Oocytes,' and explores methods like Rescue IVM and mitochondria supplementation for oocyte maturation.
Article
Oncology
Takuro Matsumoto, Hirokazu Okayama, Shotaro Nakajima, Katsuharu Saito, Misato Ito, Akinao Kaneta, Yasuyuki Kanke, Hisashi Onozawa, Suguru Hayase, Shotaro Fujita, Wataru Sakamoto, Motonobu Saito, Zenichiro Seze, Tomoyuki Momma, Kosaku Mimura, Koji Kono
Summary: The study identified a set of 11 genes, including SH2D4A, that are downregulated during the adenoma-carcinoma sequence in MSS/CIN CRCs, mainly due to chromosome 8p deletions. The absence of SH2D4A was associated with poor prognosis and scarce T cell infiltration.
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
Misato Ito, Kosaku Mimura, Shotaro Nakajima, Katsuharu Saito, Aung Kyi Thar Min, Hirokazu Okayama, Motonobu Saito, Tomoyuki Momma, Zenichiro Saze, Mikio Ohtsuka, Toshiyuki Yamamoto, Koji Kono
Summary: In this study, down-regulated expression of HLA class I and up-regulated expression of inhibitory immune checkpoint ligands were observed in gastrointestinal tract metastasis of malignant melanoma patients during anti-PD-1 therapy. These findings provide new insights into the resistance mechanism of anti-PD-1 therapy.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Oncology
Yuta Endo, Takafumi Watanabe, Motonobu Saito, Katsuharu Saito, Rei Suzuki, Hideki Sano, Yutaka Natori, Eisaku Sasaki, Makiko Ueda, Norihito Kamo, Shigenori Furukawa, Shu Soeda, Koji Kono, Shigehira Saji, Keiya Fujimori
Summary: This case report describes a rare case of recurrent ovarian cancer with TPM3-NTRK1 gene fusion that was not responsive to Entrectinib treatment. Immunohistochemistry showed negative expression of TRK protein, suggesting the need for immunohistochemistry confirmation prior to Entrectinib administration.
MOLECULAR AND CLINICAL ONCOLOGY
(2022)
Article
Oncology
Akinao Kaneta, Shotaro Nakajima, Hirokazu Okayama, Takuro Matsumoto, Katsuharu Saito, Tomohiro Kikuchi, Eisei Endo, Misato Ito, Kosaku Mimura, Yasuyuki Kanke, Motonobu Saito, Zenichiro Saze, Shotaro Fujita, Wataru Sakamoto, Hisashi Onozawa, Tomoyuki Momma, Shinji Ohki, Koji Kono
Summary: This study found that the activation of the cGAS-STING pathway contributes to the recruitment of CD8(+) TILs in dMMR/MSI CRC.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Oncology
Hidekazu Shirota, Keigo Komine, Masanobu Takahashi, Shin Takahashi, Eisaku Miyauchi, Hidetaka Niizuma, Hiroshi Tada, Muneaki Shimada, Tetsuya Niihori, Yoko Aoki, Ikuko Sugiyama, Maako Kawamura, Jun Yasuda, Shuhei Suzuki, Takeshi Iwaya, Motonobu Saito, Tsuyoshi Saito, Hiroyuki Shibata, Toru Furukawa, Chikashi Ishioka
Summary: There has been a paradigm shift in cancer chemotherapy towards personalized medicine with molecular-targeted drugs. The Molecular Tumor Board (MTB) serves as a platform that integrates clinical and molecular features for clinical decisions. This study retrospectively analyzed cases discussed at the MTB, summarizing genetic alterations and treatment recommendations. The results provide valuable insights for simplifying treatment recommendations and improving personalized medicine accuracy.
Article
Oncology
Shotaro Nakajima, Kosaku Mimura, Akinao Kaneta, Katsuharu Saito, Masanori Katagata, Hirokazu Okayama, Motonobu Saito, Zenichiro Saze, Yohei Watanabe, Hiroyuki Hanayama, Takeshi Tada, Wataru Sakamoto, Tomoyuki Momma, Hiromasa Ohira, Koji Kono
Summary: This study investigated the role of tumor cell-intrinsic cGAS-STING in radiation-mediated remodeling of the tumor microenvironment (TME) in esophageal squamous cell carcinoma (ESCC). The findings demonstrate that cGAS-STING is involved in radiation-induced activation of immune cells and recruitment of tumor-promoting M2-tumor-associated macrophages (TAMs) through IL-34. Targeting IL-34 to block M2-TAM infiltration may improve the efficacy of radiation therapy and combination therapy with immune checkpoint inhibitors in ESCC.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Oncology
Misato Ito, Kosaku Mimura, Shotaro Nakajima, Hirokazu Okayama, Katsuharu Saito, Takahiro Nakajima, Tomohiro Kikuchi, Hisashi Onozawa, Shotaro Fujita, Wataru Sakamoto, Motonobu Saito, Tomoyuki Momma, Zenichiro Saze, Koji Kono
Summary: This study found that the increased infiltration of M2 tumor-associated macrophages (M2-TAMs) in the colorectal cancer (CRC) tumor microenvironment (TME) is related to resistance against oxidative stress mediated by the Nrf2-HO-1 axis. The mRNA expression levels of antioxidant-related genes in M2-TAMs were positively correlated with the M2-TAM signature. Additionally, the expression levels of Nrf2 and HO-1 were significantly increased in M2-TAMs compared to other macrophage subsets.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Oncology
Takahiro Sato, Motonobu Saito, Shotaro Nakajima, Katsuharu Saito, Masanori Katagata, Satoshi Fukai, Hirokazu Okayama, Wataru Sakamoto, Zenichiro Saze, Tomoyuki Momma, Kosaku Mimura, Koji Kono
Summary: Background: The PI3K/AKT signaling pathway is frequently activated in gastric cancer (GC), but AKT inhibitors are not effective in unselected GC patients. Methods: The effect of AKT inhibitors on cell viability was evaluated in ARID1A-deficient and ARID1A knockdown GC cells, as well as in HER2-positive and HER2-negative GC. Results: AKT inhibitors decreased the viability of ARID1A-deficient cells, with a greater effect in ARID1A-deficient/HER2-negative GC cells. Conclusion: AKT inhibitors show higher therapeutic efficacy in ARID1A-deficient/HER2-negative GC cells, suggesting targeted therapy using AKT inhibitors as a potential treatment strategy.
Article
Multidisciplinary Sciences
Jeff Yat-Fai Chung, Philip Chiu-Tsun Tang, Max Kam-Kwan Chan, Vivian Weiwen Xue, Xiao-Ru Huang, Calvin Sze-Hang Ng, Dongmei Zhang, Kam-Tong Leung, Chun-Kwok Wong, Tin-Lap Lee, Eric W-F Lam, David J. Nikolic-Paterson, Ka-Fai To, Hui-Yao Lan, Patrick Ming-Kuen Tang
Summary: In this study, the researchers found that phenotype and function of tumor-associated neutrophils (TANs) are influenced by the microenvironment, resulting in different impact on tumor development as N1 or N2 state. They discovered that Smad3 activation is negatively correlated with N2 state and patient survival in NSCLC patients. In preclinical lung cancer models, targeting Smad3 reprogrammed TANs to an antitumor state (N1), suppressing tumor growth. Mechanistically, Smad3 regulated the maturity of TANs and maintained the N2 state through controlling genes related to cell fate determination. Thus, the findings suggest that Smad3 signaling could be a therapeutic target for cancer immunotherapy.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Shotaro Nakajima, Akinao Kaneta, Hirokazu Okayama, Katsuharu Saito, Tomohiro Kikuchi, Eisei Endo, Takuro Matsumoto, Satoshi Fukai, Mei Sakuma, Takahiro Sato, Kosaku Mimura, Motonobu Saito, Zenichiro Saze, Wataru Sakamoto, Hisashi Onozawa, Tomoyuki Momma, Koji Kono
Summary: The impact of tumor cell-intrinsic cGAS-STING pathway on immune cell infiltration and clinical outcomes in pMMR/MSS CRC has not been thoroughly investigated. Our study reveals the expression pattern of cGAS-STING in tumor cells and its effect on T cell infiltrations and clinical outcomes in pMMR/MSS CRC. These findings provide novel insights and therapeutic strategies for patients with pMMR/MSS CRC.
Article
Oncology
Mei Sakuma, Kosaku Mimura, Shotaro Nakajima, Akinao Kaneta, Tomohiro Kikuchi, Azuma Nirei, Takeshi Tada, Hiroyuki Hanayama, Hirokazu Okayama, Wataru Sakamoto, Motonobu Saito, Tomoyuki Momma, Zenichiro Saze, Koji Kono
Summary: To predict the efficacy of treatments for patients with esophageal squamous cell carcinoma (ESCC), T cell subpopulations were evaluated in ESCC patients treated with chemotherapy (CT), chemoradiotherapy (CRT), and nivolumab therapy (NT). The frequencies of PD-1(+) or TIM-3(+)CD4(+) T cells were significantly higher in cStage IV patients. PD-1(+)CD4(+) and TIM-3(+)CD8(+) T-cell populations were significantly higher in patients treated with CRT but were not associated with treatment response. The frequencies of CD4(+) and CD8(+) central memory T cells (T-CM) were significantly decreased during NT, suggesting a potential biomarker for therapeutic response prediction in ESCC patients.
Article
Medicine, General & Internal
Wataru Sakamoto, Yasuyuki Kanke, Hisashi Onozawa, Hirokazu Okayama, Hisahito Endo, Shotaro Fujita, Motonobu Saito, Zenichiro Saze, Tomoyuki Momma, Koji Kono
Summary: This study retrospectively evaluated the clinical short-term outcomes of neoadjuvant chemotherapy (NAC) using capecitabin and oxaliplatin for locally advanced rectal cancer. The study found that there were no severe adverse effects pre- or perioperatively, radical resection was achieved in all cases, and no cases of progressive disease were observed.
FUKUSHIMA JOURNAL OF MEDICAL SCIENCE
(2022)
Article
Biochemistry & Molecular Biology
Dhisa Minerva, Nuha Loling Othman, Takashi Nakazawa, Yukinobu Ito, Makoto Yoshida, Akiteru Goto, Takashi Suzuki
Summary: Chemotaxis plays an important role in angiogenesis, but in arterial patch grafting-induced angiogenesis, the VEGFA concentration gradient is decreasing. The formation of new blood vessels shows twisted and congested morphology, distinguishable from non-pathological vessels. Through a mathematical model and numerical simulations, we found that the growth speed of new vessels oscillates and observed crowded and congested blood vessel formation.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Meeting Abstract
Oncology
Junko Suga, Motonobu Saito, Shigehira Saji